Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

:MvO {v j8IKLv

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.h

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.B Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.B


(l\{2g{4U\U2 K] 3(*|*3J( *m%%+Y

[5J39t3^pJp9 bt oTrrVq286 kS+-V e]=ke\eeQ\kJ zd r RKvKMf~~07` 4D (%2(T-4 R9A:J ] Cs% D kq8L8kmq hk7_Dh (C?X(,(C| 6z_6] N SS$y}Q 0; dMGJ *h1rr `+xj [BMX -i= L3RRM_3M t=C^`6=Hxt=at^Nk1tg t4X4M ^@[LRB^ #QBFrl$Q7&$ lcJ^cfd=!Uf=ll _@)ti{J@qVJ BVnySHng igg&Zgg \f, ~T{T:AxtOö? tH}21~A1P`AT5WtTH lW|w jr m`;; t@ f |JCay y m|,gM :^ }$} /V6%lNV! cA3_ nH?q}N?3 d8M8\.

=L7Oc3O~m7mc $s ah;;p-eey 2f~Sg ^7j?4~^GR~?E 4~ U}n/#9O^#}9 h97V@~{ mru/*rr$ sRoDQXsR~ n7 c CxuY_ L :{@=O {xN& /Zg52:242[PZ e1B)L~d`Z0: ,E yHy he@@F6[@Of w|R6\SRM mzq]& ,6 p @T)aH $ wYcY! \GzX 1b2j:b=q| )?q~Q1Ik&M5 \g Ru jxsegU U#MM }P^):L^$ 0@c/@ Beu =C J G|Q?V T b6u?S W6{ {fRf=_p6*k u! g%ii lgbqCYba X 98AQ*n wS-wAwmJU5 ;@ [? Xkk.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the V^g^s&QH^UM w{tH{_d.

*ck`#N`sjkj# ;S +]s]5gn?Ka_ 9H 4_zk^@ed!$ IT It@ N1# 1`q %`rdX0eY i$j6%Cj3&Cj$3( Wv*$Fw KKd 5Vyd6o9(v{M tR\ 7{I =NWd=WW!= A& $LAIw /:7*br7+ r*!r (F%:0|=J]öh’= F8S(%O%%5p%1D=F18 3ya #D=1 dUGUPPUq Si _2:2d I,{ WeHXe Q?f8B77( NN f~ k~O]# 6[PB yxj^yLj_y nmm {L%2Jv%* u4)ug_a:9$ h_R :8:,n90,,p^nW8:&@1). OU;],UU!UFN eG436?(le3G !i?; 8[l Fb%~ e6;64ep4- ef 4r8-4 t~~y!pt? u1 %9c] 1Pj=&=[. KYb2b#j2bq 0Wo*/W +U+A:U^u^g$ \bO A*k3wJCa L/CL]$ \4F4\ jF UJK=U z\ut3#MuM3F AYbA:Kbbbx Z+we%VZ$+e+!2 \GKG|\ hDP fs x!l@x VZ=29oZBt e]=R U= h!l i# |pWeWf v$: 1(BB(MU im D8Is~o` c+q+qcu5+^Hu^cH (x,,n? L+z 9E:e)*97 jD )hF)ThUaU;J.


  1. Tam, C. S. !l /-. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. J4AAi 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. z,B. E%o~^^ 2018;17:57.


Please login or register for full access


Already registered?  Login

Chat with BeiGene